



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2361552 C 2010/06/01

(11)(21) **2 361 552**

(12) **BREVET CANADIEN  
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1999/12/14  
(87) Date publication PCT/PCT Publication Date: 2001/06/21  
(45) Date de délivrance/Issue Date: 2010/06/01  
(85) Entrée phase nationale/National Entry: 2001/07/26  
(86) N° demande PCT/PCT Application No.: JP 1999/007008  
(87) N° publication PCT/PCT Publication No.: 2001/043736

(51) Cl.Int./Int.Cl. *A61K 31/045* (2006.01),  
*A61K 9/06* (2006.01), *A61K 9/70* (2006.01),  
*A61P 25/06* (2006.01)

(72) Inventeurs/Inventors:  
YOKOYAMA, HIDEAKIRA, JP;  
HAMAMOTO, HIDETOSHI, JP

(73) Propriétaires/Owners:  
TEIKOKU SEIYAKU CO., LTD., JP;  
ROHTO PHARMACEUTICAL CO., LTD., JP

(74) Agent: KIRBY EADES GALE BAKER

(54) Titre : MEDICAMENT ATTENUANT LA MIGRAINE  
(54) Title: DRUG FOR ALLEVIATING MIGRAINE

(57) **Abrégé/Abstract:**

This invention relates to external drugs for dermal application which have a migraine-alleviating effect, in more detail ointments and patches comprising mixing 1-menthol and an essential oil into a base containing a hydrophilic high-molecular weight compound, a polyhydric alcohol and water.



## ABSTRACT

This invention relates to external drugs for dermal application which have a migraine-alleviating effect, in more detail ointments and patches comprising mixing 1-  
5 menthol and an essential oil into a base containing a hydrophilic high-molecular weight compound, a polyhydric alcohol and water.

## DRUG FOR ALLEVIATING MIGRAINE

## TECHNICAL FIELD

5       The present invention relates to an external drug for dermal application, such as ointments or patches. In more detail, the invention describes patches wherein 1-menthol and an essential oil is mixed into a base containing a hydrophilic high-molecular weight compound, a polyhydric alcohol and water. Such patches have a migraine-alleviating  
10 effect.

## BACKGROUND ART

      The cause of migraines is not clear, but it is considered that blood flow increases by expansion of head  
15 or cervix blood vessels due to hormone unbalance, and then muscle around that contracts. As a result a migraine is caused.

      For the treatment of migraine, analgesics for an internal application which contain ergotamine tartrate, dimethothiazine mesylate, caffeine, etc., as an active  
20 ingredient are used. However, such a drug is often administered for long term and therefore, there is a possibility to induce side effects such as, anaphylaxis, insomnia, or gastrointestinal disorders.

25       Accordingly, various preparations for dermal

applications for treating migraine have been worked out.

For example, in Japanese Patent Publication B 6-67835,  
a composition that methysergide, anti-serotonin is  
dispersed in a hydrophilic polymer for systemic dermal  
5 application to prevent migraine is disclosed. Furthermore,  
in Japanese Patent Publication A Tokuhyo Hei 8-509749, a  
dermally therapeutic system containing sumatriptan useful  
for migraine, cluster headache, etc., is disclosed.

However, these preparations for dermal application  
10 have a possibility to induce side effects, such as skin  
irritation, etc., when administering them over the long term  
and therefore, these preparations are not favorable.

It is known that essential oils alleviate headache in  
using as aromatherapy, but they are often not simple to use.

15

The present inventors have extensively studied in  
order to obviate the above mentioned problems, and as a result,  
have unexpectedly found that migraine can be alleviated by  
dermally administering to a human a drug containing 1-menthol  
20 and an essential oil as active ingredients. Thus, the  
present invention has been completed.

#### DISCLOSURE OF INVENTION

The drug having a migraine-alleviating effect of the  
25 present invention is a drug for a local dermal



application containing l-menthol and an essential oil as active ingredients. Its preferable preparations are ointments or patches, especially patches wherein l-menthol and an essential oil as active ingredients are mixed into a base containing hydrophilic high-molecular weight compound, a polyhydric alcohol and water.

The drug of the present invention is prepared by mixing l-menthol and an essential oil with a known base and if necessary, surfactants, preservatives, etc. to make into ointments or patches by a conventional method.

The amount of l-menthol admixed is for example, 0.01% - 1% by weight per total weight of base, preferably 0.05% - 0.5% by weight per total weight of base.

The essential oils used in the present invention are lavender oil, juniper oil, peppermint oil, rose oil, rosemary oil, etc. or a mixture thereof. The amount of these oils is 0.001% - 1% by weight per total weight of base, preferably 0.005 - 0.5% by weight per total weight of base.

In ointments, known bases such as white Vaseline™, yellow Vaseline, lanolin, purified beeswax, cetanol, stearyl alcohol, hydrogenated oil, hydrocarbon gel, polyethylene glycol, etc. are used. To these bases, l-menthol and an essential oil and if necessary, surfactants, preservatives, purified water, etc. are mixed to prepare

ointments.

The especially preferable preparations of the present invention are patch-preparations which are prepared by mixing l-menthol and an essential oil as active ingredients  
5 into the base containing a hydrophilic high-molecular weight compound, polyhydric alcohol and water.

The patches of the present invention are in more detail explained as follows.

The hydrophilic high-molecular weight compounds used  
10 in the patches include, for example, gelatin, polyacrylic acid and its salt, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium carboxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, methyl vinyl ether-maleic acid anhydride copolymer, sodium  
15 alginate, polyethylene oxide, acacia gum, xanthan gum, tragacanth gum, etc. These may be used in a mixture thereof.

The amount of the hydrophilic high-molecular weight compound is not limited, but when its amount is less than  
20 2% by weight per total weight of base, the base lacks sufficient viscosity to become a paste. On the other hand, when its amount is more than 20% by weight per total weight of base, it may occur that viscosity of the base becomes too high to smoothly prepare the preparation. Therefore, the amount of  
25 the hydrophilic high-molecular weight compound is 2-20% by

weight per total weight of base, preferably 5-15% by weight per total weight of base.

The polyhydric alcohols include glycerin, sorbitol, propylene glycol, polyethylene glycol, 1,3-butylene glycol, ethylene glycol, etc. These may be used in a mixture thereof.

The amount of the polyhydric alcohol is 8 - 60% by weight per total weight of base, preferably 10 - 50% by weight per total weight of base.

When its amount is less than 8% by weight per total weight of base, humidity-keeping effect becomes poor and water becomes volatile in a short time. On the other hand, when its amount is more than 60% by weight per total weight of base, it is difficult to mix with other substances and to use too much of the polyhydric alcohol is not desirable.

The amount of water is 20 - 80% by weight per total weight of base, preferably 25 - 70% by weight per total weight of base.

When its amount is less than 20% by weight per total weight of base, dissolution of the hydrophilic high-molecular weight compound is not satisfactory and it is impossible to homogeneously extend the base. On the other hand, when its amount is more than 80% by weight per total weight of base, it may occur that the base becomes too soft to spread out. Therefore, it is not desirable to use much water.



The amount of l-menthol is 0.01-1% by weight per total weight of base, preferably 0.05-0.5% by weight per total weight of base as mentioned above. The amount of the essential oil is 0.001-1% by weight per total weight of base, preferably 0.005-0.5% by weight per total weight of base as mentioned above.

In addition to the above mentioned base, the following additives which are usually used in patches can be mixed in the usual amount: excipients (kaolin, bentonite, titanium oxide, etc.), surfactants (glycerin fatty acid ester, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, sorbitan fatty acid ester, polysorbate 80, polysorbate 60, sorbitan sesquioleate), crosslinking agents (multivalent metal such as aluminum hydroxide, aluminum glycinate, dihydroxyaluminum aminoacetate, synthetic hydrotalcite, etc.), coloring agents (new coccin, tartrazine, brilliant blue FCF), and preservatives (p-hydroxybenzoic acid ester, sorbic acid salt, isopropyl methyl phenol, hinokitiol, phenoxyethanol, etc.)

The base is prepared by mixing each ingredient in accordance with a conventional method. For example, a part of a hydrophilic high-molecular weight compound and a polyhydric alcohol are dissolved in water, and if desired, other additives are mixed, and then l-menthol and an



essential oil are added to the mixture to be kneaded. Then, residual of the hydrophilic high-molecular weight compound and other additives are mixed thereto to prepare the base.

5 The base thus prepared is spread on an appropriate support and a releasing paper is put on the base in order to protect the base. The base is cut into a fixed size to prepare desired patches.

The amount of the base in patches is 200-5000g/m<sup>2</sup>, preferably 500-2000g/m<sup>2</sup>.

10 The support is one such as non-woven fabrics, fabrics, knits, etc., used in usual patches. Its material can be a synthetic fiber such as nylon, rayon, polyester, polypropylene, etc. or a natural fiber such as cotton. As the releasing paper, a plastic film such as polyethylene film, etc. and others used in usual patches are used.

15 Shapes of the patches may be ellipse, rectangle, triangle, boomerang type, facemask type, etc.

The patches of the present invention are preferably applied to the forehead, nape of the neck, temple, a half of face and/or full face, and by applying the patch thereto, a  
20 migraine-alleviating effect effectively appears.

#### BEST MODE FOR CARRYING OUT THE INVENTION

The present invention and its effect are  
25 illustratively explained by working examples and tests, but

the invention should not be limited by these examples.

#### Examples 1-6

Using ingredients shown in Tables 1 and 2, patches (Examples 1-6) were prepared by a conventional method.

5 Namely, a part of the hydrophilic high-molecular weight compound and the polyhydric alcohol were dissolved in purified water, and if necessary, other ingredients were added thereto. The mixture was fully kneaded. Then, l-menthol and the essential oil were added to the mixture and  
10 further, the residue of the hydrophilic high-molecular weight compound and other ingredients were added thereto. Finally, the residue of the purified water was added to the mixture. The mixture was homogeneously kneaded to prepare a base.

15 The base prepared was spread on the support (1000g/m<sup>2</sup>) and a releasing paper or plastic film was put on it. The base was cut into a fixed size to prepare patches.

The bases prepared above, as such may be used as ointments.

Table 1.

Ingredients	Percent by Weight		
	Example 1	Example 2	Example 3
Polyacrylic acid	1.0	2.5	1.25
Sodium polyacrylate	5.0	6.0	6.0
Sodium carboxy methylcellulose	5.0	4.0	5.5
Gelatin	0.4	-	0.2
Polyvinyl alcohol	0.2	-	-
Tartaric acid	0.2	0.15	0.25
Disodium edetate	0.1	0.08	0.07
Glycerin	22.0	15.0	18.0
70% Sorbitol solution	-	15.0	-
Aluminum hydroxide	0.3	-	-
Synthetic hydrotalcite	-	0.2	-
Dihydroxyaluminum acetate	-	-	0.08
Polysorbate 80	0.1	0.1	0.1
Castor oil	0.5	0.5	0.5
Methylparaben	0.1	0.1	0.1
l-Menthol	0.3	0.15	0.1
Peppermint oil	0.2	-	-
Rose oil	-	0.1	-
Lavender oil	-	-	0.01
Purified water	Residue	Residue	Residue
	100	100	100

Table 2.

Ingredients	Percent by Weight		
	Example 4	Example 5	Example 6
Polyacrylic acid	1.5	2.0	1.25
Sodium polyacrylate	5.0	5.5	6.0
Sodium carboxy methylcellulose	5.0	4.0	5.5
Gelatin	-	-	-
Polyvinyl alcohol	0.2	-	-
Tartaric acid	0.2	0.15	0.3
Disodium edetate	0.1	0.08	0.07
Glycerin	20.0	15.0	20.0
70% Sorbitol solution	10.0	15.0	-
Aluminum hydroxide	0.3	-	-
Synthetic hydrotalcite	0.15	-	-
Dihydroxyaluminum acetate	-	0.1	0.1
Polysorbate 80	0.1	0.1	0.1
Castor oil	0.5	0.5	0.5
Methylparaben	0.1	0.1	0.1
l-Menthol	0.8	0.25	0.05
Peppermint oil	0.2	0.4	-
Rose oil	-	0.4	0.05
Lavender oil	0.05	-	0.1
Purified water	Residue	Residue	Residue
	100	100	100

## Comparative example 1

The patch was prepared by the same method as Example 1

5 using the same ingredients as Example 1 provided that the



same amount of water as l-menthol was used instead of l-menthol (Only an essential oil is used as an active ingredient).

5 Comparative example 2

The patch was prepared by the same method as Example 1 using the same ingredients as Example 1 provided that the same amount of water as an essential oil was used instead of the essential oil (Only l-menthol is used as an active  
10 ingredient).

Comparative example 3

The patch was prepared by the same method as Example 1 using the same ingredients as Example 1 provided that the  
15 same amount of water was used instead of the essential oil and l-menthol (Any active ingredient was not used).

Next, each two patches (5x7cm) of Examples 1, 3, 5 and Comparative examples 1-3 were put on each volunteer. The  
20 following items were sensitively evaluated.

Test 1

On the foreheads of ten volunteers suffering from migraine were placed each patch of Examples 1, 3, 5 and  
25 Comparative examples 1-3, and migraine-alleviating effect

was evaluated by sensory test under the following evaluation-standards.

Evaluation-standard on effects

Point 1: no effect

5 Point 2: weak effect

Point 3: effective

Point 4: clearly effective

Point 5: strongly effective

10 Efficacy (point) was indicated by the average of volunteer's evaluations. The duration of the effect was indicated by the average of volunteer's reported times.

The result was shown in the following Table 3.

Table 3

	Efficacy(point)	Duration of effect(hour)
Example 1	4.2	7.3
Example 3	4.3	7.9
Example 5	3.9	6.5
Comparative example 1	2.5	3.2
Comparative example 2	2.8	2.8
Comparative example 3	1.3	2.1

15 As is clear from the result of Table 3, patches of Examples 1, 3 and 5 were superior in efficacy (point) to patches of Comparative examples 1-3, and therefore, it is

recognized that patches of Examples 1, 3 and 5 are excellent in migraine-alleviating effect and that its effect lasts for long hours.

## 5 Test 2

On various regions of ten volunteers suffering from migraine were placed each patch of Examples 1, 3, 5 and Comparative example 3, and migraine-alleviating effect depending on the region was evaluated by sensory test under  
10 the following evaluation-standards.

Evaluation standard:

+ : Positive alleviating efficacy

± : Weak alleviating efficacy

- : No alleviating efficacy

15 The result is shown in Table 4.

Table 4.

Application region	Alleviating efficacy			
	Example 1	Example 3	Example 5	Comparative example 3
Forehead	+	+	+	±
Nape of neck	+	+	+	-
Temple	+	+	+	±
Shoulder	±	±	±	-
Back	-	-	-	-
Breast	-	-	-	-

As is clear from the result of Table 4, when applying the preparations of the present invention, that is preparations of Examples 1, 3 and 5 to face, nape of the neck and temple, the preparations were recognized being superior in migraine-alleviating efficacy. On the other hand, a patch of Comparative example 3 hardly showed migraine-alleviating efficacy in any region.

#### INDUSTRIAL APPLICABILITY

The preparation of the present invention is excellent in migraine-alleviating efficacy, and even when used over the long term, there is hardly a possibility to induce side effects and the preparation of the present invention is very convenient and useful.



## CLAIMS

1. An external migraine-alleviating drug for local application, consisting of l-menthol and at least one  
5 essential oil selected from the group consisting of lavender oil, juniper oil, peppermint oil, rose oil and rosemary oil, as active ingredients.

2. The drug claimed in claim 1, wherein the external  
10 migraine-alleviating drug for local application is an ointment.

3. The drug claimed in claim 1, wherein the external  
migraine-alleviating drug is in a patch.

4. The drug claimed in claim 1, wherein the external  
migraine-alleviating drug for local application is prepared  
by mixing l-menthol and the essential oil as active  
ingredients into a base containing a hydrophilic high-  
20 molecular weight compound, a polyhydric alcohol and water.

5. The drug claimed in claim 4, wherein the amounts of  
l-menthol and the essential oil are 0.01-1% by weight per  
total weight of base and 0.001-1% by weight per total  
25 weight of base, respectively.

6. The drug claimed in claim 4, wherein the amounts of the  
hydrophilic high-molecular weight compound is 2-20%, of the  
polyhydric alcohol is 8-60% and of water is 20-80%  
30 percentages are by weight based on the total weight of  
base.

7. The drug claimed in claim 3, wherein shape of the patch is rectangle, ellipse, triangle, boomerang type or facemask type.

5 8. Use of only l-menthol and at least one essential oil selected from the group consisting of lavender oil, juniper oil, peppermint oil, rose oil and rosemary oil, as active ingredients for preparing an external migraine-alleviating drug for local application.

10 9. The use claimed in claim 8, wherein the external migraine-alleviating drug for a local application preparation is a patch.

15 10. The use claimed in claim 8, wherein the external migraine-alleviating drug for a local application preparation is in an ointment.

20 11. Use of a drug containing l-menthol and at least one essential oil selected from the group consisting of lavender oil, juniper oil, peppermint oil, rose oil and rosemary oil, to alleviate migraine.

25 12. The use claimed in claim 11, wherein the drug is in a patch.

13. The use claimed in claim 11, wherein the drug is suitable for dermal application.

30 14. The use claimed in claim 11, wherein the drug is suitable for application to face, forehead, nape of the neck or temple.

15. The drug claimed in claim 1, wherein the external migraine-alleviating drug for local application is in an ointment prepared by mixing l-menthol and the at least one essential oil selected from the group consisting of lavender oil, juniper oil, peppermint oil, rose oil and rosemary oil, as active ingredients into a base containing a hydrophilic high-molecular weight compound, a polyhydric alcohol and water.

16. The drug claimed in claim 15, wherein the amounts of l-menthol and the at least one essential oil are 0.01-1% by weight per total weight of base and 0.001-1% by weight per total weight of base, respectively.